PHARMACEUTICAL COMPOSITION COMPRISING A LTB4 ANTAGONIST AND A COX-2 INHIBITOR OR A COMBINED COX 1/2 INHIBITOR

The invention relates to a pharmaceutical formulation comprising a LTB4 antagonist having a hydroxy and a benzamidine group or a tautomer, a pharmaceutically acceptable salt or solvate thereof, in particular a compound of formula (I), wherein R and A are as defined in the claims, or a tautomer, a pharmaceutically acceptable salt or solvate thereof (1) and at least one cyclooxygenase-2 inhibitor, a combined cox1/2 inhibitor or a pharmaceutically acceptable salt or solvate thereof (2), and a pharmaceutically acceptable carrier or excipient, and optionally one or more other therapeutic ingredients. Ovaj pronalazak se odnosi na farmaceutsku formulaciju koja obuhvata LTB4 antagonist koji ima hidroksi i benzamidin grupu ili njegov tautomer, farmaceutski prihvatljivu so, solvat, ili fiziološki funkcionalni derivat, posebno jedinjenje sa formulom (I) u kojoj R i A su kako je definisano u zahtevima, ili njihovi tautomeri, farmaceutski prihvatljive soli, solvati, ili fiziološki funkcionalni derivati (1) i najmanje jedan ciklooksigenaza-2 inhibitor, kombinovane koksl/2 inhibitore ili njihove farmaceutski prihvatljive soli, solvate, ili fiziološki funkcionalne derivate (2), i farmaceutski prihvatljivi nosač ili ekscipijent, i opciono jedan ili više drugih terapeutskih sastojaka.